Gilead Sciences reported second quarter 2026 total revenues of $7.8 billion, a 10% increase year-over-year, driven by HIV product sales growth of 12% and strength in Trodelvy and Livdelzi. Biktarvy sales rose 7% to $3.8 billion, while Descovy sales surged 48% to $967 million. The company reported a diluted loss per share of $(8.45), primarily due to $11.2 billion in acquired in-process research and development expenses from the Arcellx, Tubulis, and Ouro Medicines acquisitions. Gilead updated its full year 2026 guidance, raising product sales expectations to $30.1–$30.4 billion but lowering diluted loss per share estimates to $(3.75)–$(3.40). The Board declared a quarterly dividend of $0.82 per share for the third quarter of 2026, payable on September 29, 2026, to shareholders of record as of September 15, 2026. Gilead Sciences is a biopharmaceutical company focused on HIV, viral hepatitis, oncology, and inflammation treatments.

Gilead Sciences has entered into an agreement to issue $3 billion in aggregate principal amount of senior notes to fund general corporate purposes. The offering consists of $500 million due 2028 at 4.250%, $1 billion due 2029 at 4.400%, $1 billion due 2031 at 4.600%, and $500 million due 2034 at 4.900%.

Gilead Sciences announced its financial results for the quarter ended March 31, 2026. The company's specific financial performance and non-GAAP reconciliations are detailed in the accompanying press release.

Gilead Sciences held its 2026 annual meeting of stockholders on April 30, resulting in the election of nine directors and the ratification of Ernst & Young LLP as the company's independent auditor. Shareholders also approved executive compensation and the amended 2022 Equity Incentive Plan, but rejected several stockholder proposals regarding board leadership and ESG/DEI reporting.

Gilead Sciences completed its acquisition of Arcellx, Inc. on April 28, 2026, for an aggregate transaction value of approximately $7.1 billion. Shareholders received $115.00 per share in cash plus one contingent value right (CVR) worth $5.00, which is payable if cumulative worldwide sales of the anito-cel product exceed $6.0 billion by December 31, 2029.

Gilead Sciences has entered into a definitive merger agreement to acquire Arcellx, Inc. through a tender offer priced at $115.00 per share in cash. Additionally, shareholders will receive one contingent value right (CVR) per share, which offers a potential $5.00 cash payment upon the achievement of specific sales milestones for the product anito-cel by December 31, 2029.